CBS 2019
CBSMD教育中心
English

动脉粥样硬化性心血管疾病预防

科研文章

荐读文献

Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular DiseaseA Prespecified Analysis From the FOURIER Trial Adenosine and adenosine receptor-mediated action in coronary microcirculation Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality Association of Sustained Blood Pressure Control with Multimorbidity Progression Among Older Adults 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes Clinical Risk Factors and Atherosclerotic Plaque Extent to Define Risk for Major Events in Patients Without Obstructive Coronary Artery Disease: The Long-Term Coronary Computed Tomography Angiography CONFIRM Registry 2019 Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases developed in collaboration with the EASD ESC Clinical Practice Guidelines Myocardial bridging of the left anterior descending coronary artery is associated with reduced myocardial perfusion reserve: a 13N-ammonia PET study

Original Research2021 Mar 25;cvab100.

JOURNAL:Cardiovasc Res. Article Link

Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics

DI Swerdlow, DA Rider, A Yavari et al. Keywords: lipoprotein(a)-mediated cardiovascular disease; treatment option; RNA interference therapeutics

Full Text PDF